Clinical efficacy of intratympanic steroid injection for treating idiopathic sudden sensorineural hearing loss

J Chin Med Assoc. 2024 Mar 1;87(3):328-333. doi: 10.1097/JCMA.0000000000001061. Epub 2024 Jan 29.

Abstract

Background: Idiopathic sudden sensorineural hearing loss (ISSNHL) is an emergency that causes permanent hearing loss if timely treatment is not provided. However, the evidence supporting the effect of intratympanic steroid injection (ITSI) starting time on hearing outcome is limited.

Methods: We retrospectively enrolled 582 patients with ISSNHL who were treated with ITSIs and reviewed their clinical and audiological variables. The relationship between ITSI starting time and hearing recovery was analyzed.

Results: The mean starting time of ITSI was 13.17 ± 16.53 days. The overall hearing recovery rate was 55.15% (recovery = mean hearing level gain of ≥10 dB). The recovery rates were 79.2%, 67.4%, 50%, 36.6%, and 17.8% for the ITSI starting times of 1 to 3, 4 to 7, 8 to 14, 15 to 28, and ≥29 days, respectively. A multivariate analysis revealed that ITST starting time (odds ratio [OR] = 0.94, 95% CI, 0.92-0.96, p < 0.001) and salvage therapy (OR = 0.55, 95% CI, 0.35-0.86, p = 0.009) were independent poor prognostic factors for patients with ISSNHL.

Conclusion: Earlier ITSI treatment is associated with a higher hearing recovery rate. Comorbidities and post-ITSI complications were nonsignificant independent risk factors.

MeSH terms

  • Dexamethasone
  • Glucocorticoids / therapeutic use
  • Hearing Loss, Sensorineural* / drug therapy
  • Hearing Loss, Sensorineural* / etiology
  • Hearing Loss, Sudden* / drug therapy
  • Humans
  • Retrospective Studies
  • Steroids / therapeutic use
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Dexamethasone
  • Steroids